coronavirus vaccine, US drugmaker Johnson & Johnson's chief scientist said the company is recruiting more than 1,000 people per day.
The drug firm also expects to have all the data needed to seek US authorisation by February next year or earlier."By the end of the year or around the end of the year, we should have 60,000 people in the study," news agency Reuters quoted J&J's chief scientific officer Dr.
Paul Stoffels."And efficacy endpoint should be there in the first few weeks or months, January or February, of the new year," Stoffels added.Phase III trialThe Phase III trial of the single-dose vaccine started in late September.